Streamlined Acquisition of AusCann Assets
Filed with ASX · · 6 pages · English
• Argent has signed a binding agreement with AusCann for a streamlined transaction to acquire AusCann’s 48% equity interest in CannPal for $2m in RGT shares at a price of 10c per RGT share. • New, highly focused transaction supersedes the broader non-binding term sheet announced on 19 August 2025 and does not include AusCann’s equity interest in EuroCann (an EU GMP cannabis manufacturing and sales
Story so far
Earlier from Argent Biopharma
- A$11m Financing Facility to Complete Strategic Acquisition
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4E and 2025 Annual Report
- Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
- U.S. In Vivo Study Supports ArtemiC Efficacy
Later from Argent Biopharma
- CannEpil - Largest Commercial Shipment Arrives in Ireland
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- Half Yearly Report and Accounts
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- CannEpil Global Licence Expands into Veterinary Healthcare
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma